Sanofi's diabetes drug Toujeo gets U.S. approval, label disappoints

February 26, 2015 11:04 AM

3 0

(Reuters) - Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult.

Toujeo is a more potent follow-up to the French drugmaker's top-selling Lantus insulin product, which accounts for a fifth of group sales and is due to go off U.S. patent this year.

Also read: Saudi's Arab National Bank Q4 profit falls 4.9 pct, misses forecasts

Read more

To category page